Abstract: This paper is an overview of advances and prospects in applications of nanotechnology for cancer prevention, detection and treatment. We begin with a brief description of the underlying causes of cancer. Then we address preventive treatment, disease-time treatment, and diagnosis in the context of some of the most recent advances in nanotechnology. Nanoparticle science is also briefly addressed as the foundation upon which most nanotechnology cancer therapy is based. It is demonstrated how nanotechnology can help solve one of the most challenging and longstanding problems in medicine, which is how to eliminate cancer without harming normal body tissue.
Introduction
According to the US National Cancer Institute (OTIR, 2006 ) "Nanotechnology will change the very foundations of cancer diagnosis, treatment, and prevention". We have already seen how nanotechnology, an extremely wide and versatile field, can affect many of its composing disciplines in amazingly innovative and unpredictable ways. In fact, nanotechnology and the ideas and methods that it encompasses can be applied to almost any problem that leading researchers face today. Even the most seemingly impossible problems like HIV and cancer become only obstacles in the path to solutions, if we take an imaginative approach. Of course, this is quite logical, since everything around us is made up of atomic and molecular matter, and all of our problems are ultimately rooted in atomic and molecular arrangements. Nanotechnology has at last provided a way for us to rearrange and restructure matter on an atomic scale, allowing us to reach down to the very roots of any problem. Provided that we can thoroughly understand the problem on an atomic scale and develop the know-how to turn our innovative ideas for the perfect solution into reality, we now have all the tools that we need (Mansoori, 2005; Ferrari, 2005; Mansoori and Soelaiman, 2005) .
The question is what this powerful new interdisciplinary collection of technology and ideas can do to help us find cures for the worst of our diseases? The answer is with nanotechnology, we finally have the ability to understand malfunctions of the most complex biological systems at the atomic and molecular level. As we progress further into our research, the ability to devise progressively more innovative and ingenious atomic-scale solutions and to make them real will allow us to develop amazingly complex and effective weapons against any ailment. However, the field of nanotechnology is still quite young and we are only beginning to understand its capabilities and potentials.
The focus of this paper is cancer, which is one of the most widely researched diseases in today's medical and scientific community. The purpose of this paper is to discuss some of the more recent and innovative solutions that have been made possible by the advent of nanotechnology, and to offer some suggestions for further venues of research.
Genetics of cancer
Before we delve fully into the main issue of this report which deals with applications of nanotechnology in cancer prevention, detection and treatment, we must address the underlying causes and the genetic mechanisms involved in cancer. In here we present an over-simplified version of what is known on the genetics of cancer for the sake of brevity.
The word cancer was first applied to the disease by Hippocrates (460-370 B.C.), the Greek philosopher, who used the words carcinos and carcinoma to refer to non-ulcer forming and ulcer forming tumours. The words refer to a crab, probably due to the external appearance of cancerous tumours, which have branch-like projections that resemble the claws of a crab.
In non-cancerous tissues growth is limited in the sense that cell reproduction is tightly controlled. After a certain number of cells have developed, feedback control (contact inhibition) limits cell division, allowing for tissue repair but not expansion.
Cancer or neoplasm, on the other hand, involves tissues composed of cells that divide and/or grow abnormally.
Cancer is a genetically rooted disease that involves the simultaneous occurrence of two general categories of cellular malfunctions. The precise number of genetic changes required for these malfunctions remains unresolved for any cancer, but for adult cancers it is generally believed to range from 5 to 15 (Souhami et al., 2004; Fu et al., 2005) . What we present here is a brief introduction to the subject.
The first category causes the replication of a cell to become permanently enabled due to a natural or carcinogen-induced genetic mutation, chromosome translocation or gene amplification (genetic instability). The second category is also due to genetic mutations, and causes the apoptosis complex, also known as the suicide complex, to become permanently disabled ( Figure 1 ). As stated, both of these problems must occur in the same cell, at the same time, in order to cause cancer. Under normal circumstances, the cells carefully control their divisions using apoptosis complex activated by the p53 tumour suppressor protein. There are other mechanisms triggering the apoptosis complex, including receptor mediated death, which is dependant to chemical messengers, especially tumour necrosis factors (Souhami et al., 2004; Fu et al., 2005) . But, when both of these mechanisms malfunction, the body has no other option. As the uncontrolled cell division continues, a cluster of fairly unspecialised cells committed to dividing develops and becomes larger and larger. In addition, the cluster of cells releases chemicals to promote abnormal capillary growth into the tumour. This kind of a cell cluster is known as a malignant tumour, and can severely damage the surrounding tissue as it sucks up essential nutrients and displaces healthy cells. Eventually, when the tumour grows large enough, some of the tumour cells can find their way into the bloodstream, forming tumours in other parts of the body. This latter phenomenon is known as metastasis. It effectively multiplies the cancer as well as its effects, and eventually will prove fatal to the patient.
Figure 1
In this illustration, we can see how even a single nucleotide base inserted (or removed) out of sequence can cause the entire subsequent chain of amino acids, which are the building blocks of proteins, to be incorrect. When this happens in the gene sequence that codes for the protein(s) responsible for apoptosis or damping cell division, the cell permanently loses the ability to carry out that particular function (image source: http://ghr.nlm.nih.gov/ghr/). It must be added that many other mutations can be also cancerous
If we zoom in further on the genetic processes of the cell, we see that the DNA (deoxyribonucleic acid) molecule is involved in nearly all of them. The same DNA is contained inside just about every cell of a particular patient, with the only possible differences being the random mutations mentioned above. DNA, which is the genetic blueprint of the structure and function of every cell, is made up of a sequence of nucleotide bases that collectively code for the production of a myriad of proteins. Some of these macromolecules serve as catalysts in various biochemical reactions that occur within the cell. Others travel to the membrane and imbed themselves there in order to serve as transport channels for various molecules that need to travel into and out of the cell. Still others serve to decode the DNA strand in order to produce other proteins, or to copy the DNA molecule itself during cell division. Out of all these proteins, the ones that are of interest to cancer research are those responsible for reactions that occur during apoptosis, and those that are active during cell division. Each of these groups of proteins is coded for by a gene complex, which is a group of genes, controlled by a genetic switch known as an operon (Figures 2 and 3 ). There are different kinds of operons, but in general, the presence or absence of a certain substance within the cell causes a repressor protein to bind to the operator region of the complex, preventing the transcription of the genes that are found downstream in the sequence.
In the scenario where we have uncontrolled cell division, a mutation occurs in the operator region of the cell division operon, thus making it impossible for the repressor to bind, or in the regulator region, which is the genetic sequence that codes for the repressor protein itself. If one, the other, or both of these mutations occur, the proteins responsible for division are produced continuously, and the cell continuously divides.
Figure 2
The shape of a protein is what allows it to fulfill its specific function. Every protein is unique and specially tailored to participate in certain complex biochemical reactions. A difference in the sequence of amino acids that make up a protein results in a difference in shape, thus altering or destroying the functionality of the protein.
Although in some cases a point mutation may not cause a change in the amino acid sequence, and in others a change in the sequence may not cause a change in functionality, in a vast majority of cases even the slightest change will render the protein useless Figure 3 In the general model of an operon, a sequence of genes is turned on by the presence of a specific substance. The repressor protein, which is normally attached to the operator region, and which prevents transcription, is deformed by the substance, and can no longer stay bound. When this occurs, the transcription of the complex proceeds unhindered, and the proteins that are coded for by the rest of the sequence are made via the transcription/translation process. There is a subsequent feedback loop where an excess of the product causes either the same repressor or a complementary repressor to bind to the operator region and prevent further transcription/translation
In the scenario where the cell loses its ability to undergo apoptosis, the mutation can occur in the sequence that codes for proteins responsible for this cell function. In this case however, a defective repressor is not the issue, since that would only cause the cell to die prematurely. The problem occurs when the mutation is within the sequence that actually codes for the proteins. Because the structure of a protein and its function are directly related to the sequence of amino acids from which it is made, even a single mutation will almost always cause drastic changes in the protein's structure and function ( Figure 2 ). Defective proteins made from the mutated sequence can limit or even destroy the cell's ability to undergo apoptosis. If the body subsequently tries to eliminate the cell, the mechanism that actually carries out the suicide is out of order, and the cell does not respond. Taken simultaneously, these malfunctions result in a cell population that is dividing regardless of chemical signals sent by the body, and which is simultaneously non-responsive to the body's attempts to eliminate it. Within this population, every daughter cell contains the precise genetic code of the mother cell, including the mutations, so the problem persists with each subsequent generation of cells. Just such a population of cells is known as a malignant tumour or as cancer.
Telomerase
Research has led to identification of an extraordinary enzyme named telomerase that acts on telomeres (the tips of chromosomes) and is thought to be involved in the maintenance of many human cancers. Unusually high levels of telomerase activity are found in cancer cells compared to normal cells. The function of telomerase enzyme has been a mystery that's long baffled cancer researchers. It is known that greater telomere length is associated with immortalised cell lines such as embryonic stem cells and cancer cells.
The telomeres progressively shorten as cells divide and differentiate as per their normal lifespan (Kim et al., 1994; Shay and Bacchetti, 1997) .
It is believed telomerase switches on cancer cells and is key to the spread of the majority of cancers (Figure 4) . It is likely that if cancer cells made telomerase, they would retain their telomeres and would potentially survive. The presence of telomerase in various human cancers and its absence in many normal cells indicate it to be a good target for anticancer drugs and useful for cancer diagnostics, as will be discussed later in this report (Greider and Blackburn, 1996) . Specifically, we shall look at the currently-available methods, and see if nanotechnology can be used to make them safer and more effective. In addition, we are interested in methods involving nanotechnology that are entirely novel and thus unparalleled by anything that has been explored previously.
Nanotechnology preventive approach
In general, the best way to eliminate a problem is to eliminate the cause. In cancer, the problem can be perceived differently at various stages of the disease. Most apparently, if genetic mutations are the underlying cause, then we must counteract the causes of the mutations. Unfortunately, genetic mutations are caused by artificial or natural carcinogens only some of the time. At other times, they may occur spontaneously during DNA replication and cell division. With present science and technology there is very little we can do to prevent this from happening. However, in all other cases, eliminating the carcinogens is indeed a highly effective way of cancer prevention. But most patients do not recognise the problem until it has actually occurred, which makes preventive medicine a rarely utilised, although a highly effective form of cancer prevention. Even so, is there a way to eliminate cancer through nanotechnology before it starts? Although there is little current research on preventive treatments using nanotechnology, they are indeed possible. After a careful review of the most advanced disease-time nanoscale treatment methods, one can easily see why the proposed nanotechnology alternatives to current preventive treatments have so strongly attracted the attention of the scientific and medical communities in recent years. In fact, nanotechnology-based treatments are no more challenging to devise than the currently used disease-time treatment methods. Nonetheless, it requires time and monetary investments to develop such treatment methods in short time.
To demonstrate the viability of the nanotechnology-based treatments, let us consider melanoma for example. Melanoma, a form of skin cancer, is caused primarily by ultraviolet radiation from the Sun ( Figure 5 ). The current method of preventive treatment against bombardment with this kind of harmful radiation involves suspending a substance that either absorbs or scatters ultraviolet radiation in a thick emulsion. We use this emulsion, called sunscreen, to coat our skin prior to prolonged exposure to sunlight. Some of the problems with this method are that this emulsion can be easily rubbed off and can loose its effectiveness over time, thus needing to be reapplied periodically.
An even bigger problem is that we leave openings in the sunscreen coating during sunscreen application due to macro-scale and micro-scale imperfections in our skin. This allows the Ultra Violet (UV) radiation to permeate through the dead layer of skin, spreading out to a wider area due to slit diffraction and causing more widespread damage. All of these problems take away from the overall effectiveness of this preventive method.
Figure 5 UV radiation is one of the most prominent causes of DNA damage. Since UV radiation is high frequency and thus high energy, it can easily damage the delicate DNA double helix. Individual nucleotide bases readily absorb UV radiation and can become excited after even short-term exposure. This can cause hydrogen bonds between the two complementary chains, and sometimes even the covalent bonds between the phosphate backbone and the ribose to break, causing genetic mutations. The result a mutated genetic sequence and the production of defective proteins Source: http://earthobservatory.nasa.gov/Library/UVB/Images/ dna_mutation.gif Some very recent works have shown that it is possible to tag specific types of cells with nanoparticles by conjugating them to targeting agents designed to recognise cell-specific surface proteins (Greider and Blackburn, 1996) . Nanoparticles attached to desired drugs or substances can be conjugated to short peptide chains, proteins or artificial nanobodies. If we manufacture nanoparticles attached to UV scattering substances like zinc oxide (ZnO) and titanium oxide (TiO 2 ), or UV absorbing substances like octyl methoxycinnamate and oxybenzone ( Figure 6 ), and specifically target these nanoparticles to skin cell surface proteins, we can effectively coat these cells with sunscreen on the nanoscale. With this nanotechnology-based preventive treatment method, we would effectively eliminate most of the problems mentioned above. If the cells can be coated directly, the problem of diffraction in case where an area is sparsely coated will be eliminated. The most important issue to consider in this form of treatment is, of course, the toxicity of the substance that is used. The biochemical effects of a substance on the patient's health must be thoroughly evaluated by standard laboratory testing procedures as well as clinical trials before this treatment can be safely implemented. Of course, this is a purely theoretical suggestion, which is based on works that are unrelated to skin cells. It is proposed simply as an example of the potential application of nanotechnology. However, if this method can indeed be turned into reality, the obvious result will be a large reduction in the incident of melanoma due to the sun's radiation. We now have the ability to quickly and easily map large proteins and model them in three-dimensional space (Gupta et al., 2005) , as well as extensive knowledge of atomic and molecular interactions (Rafii-Tabar and Mansoori, 2004) , electronic cloud distributions (Aquilanti et al., 1989) . We also have the ability to sequence and manufacture nucleic acid and peptide chains quite easily (Lebl and Hachmann, 2001) . Taken together, these techniques give us all that we need in order to specifically target any type of animal cell, provided that it can be distinguished from other cell types by the presence of at least one cell-specific surface protein. Thus, the method discussed above is but one example of many possible applications of the fascinating new nanotechnology known as nanobiotechnology.
Nanotechnology approaches for cancerous cell destruction
Preventive treatments are not much good to those who have already developed the disease. And since these are the people who require the most immediate medical help, it is no wonder that a majority of innovative treatments are focused here. Again, there are several ways to view the problem. The traditional approach is to simply eliminate the causing agents, or the cells that make up the tumour and end their pararcine signalling effect. This method actually dates back to the mid-17th century, when John Hunter, a Scottish surgeon first suggested the surgical removal of the tumour (Denmeade and Isaacs, 2002) . Of course, we have made great progress in the last 350 years, but the idea remains the same. If we see the cancerous cells of the tumour as the causing agents of the disease, then the obvious strategy is to remove or to destroy them. The most significant recent breakthroughs have been made in this area. A relatively long-standing strategy dating back to the 1950s is to flood the body with substances that are especially toxic to tumour cells. Unfortunately, tumour cells are not dissimilar enough from healthy cells to distinguish one from the other using such large-scale techniques. A drug that is especially toxic to tumour cells is usually also toxic to healthy cells, and simply flooding the entire body with it causes system-wide damage and serious side effects. Almost everyone has heard of or seen chemotherapy patients who have lost their hair, lost significant weight, or developed other serious disorders. It is a common problem and in fact, we have also taken similar approaches to treating other seemingly incurable diseases such as AIDS and Hepatitis C, with similar results. A currently popular treatment for AIDS is a drug cocktail, or a combination of several different drugs, each somewhat effective against the disease. Administered together, these drugs can be effective, but taken constantly in large doses they can also be very damaging to the overall health of the patient. The most commonly used Hepatitis C treatment is as severe.
Two of the major drugs used to treat these diseases are Inteleukin-2 and Interferon, and some but not all of the side effects include a weakened immune system, loss of appetite, severe aches, pains, and flu-like symptoms, headaches, heart problems, stomach and digestive tract problems, eye problems, and hair loss, to list just a few (Gougerot-Pocidalo et al., 1994; Pyrhönen et al., 1999) . These alone have some experts furrowing their eyebrows, but in addition, many of these treatments have varying levels of psychological effects. While some patients are highly resistant and are lucky enough to get through the treatment with mild to moderate depression, others are plagued with severe depression, irritability, paranoia, insomnia, and even suicidal and homicidal tendencies. A select few are actually driven to suicide or homicide during or immediately after treatment. Yet the biggest setback is that these treatments are effective only some of the time, with the highest success rates ranging only from 25% to 75%. With such poor results, there is a pressing need for newer and more effective forms of treatment. While the subsequent discussion addresses research of treatments specific to cancer, nanotechnology does have the capability to deal with, both, AIDS and Hepatitis C as well as many other problematic conditions that currently have the medical community perplexed and frustrated (Gougerot-Pocidalo et al., 1994; Pyrhönen et al., 1999) . Some recent works have explored cancer treatments from nanotechnology perspectives. We shall discuss three of them here:
• The first method involves nanoparticles loaded with Paclitaxel (Figure 7 ), a common agent used to treat prostate cancer (Sahoo et al., 2004) . This research compared the efficacy of Paclitaxel-loaded nanopartlicles to Cremophore EL, a currently used colloidal suspension of the drug. The research was conducted on living mice, and is therefore relevant to consider research for actual in vivo treatment of prostate cancer in human patients. Paclitaxel was originally used by simply flooding the system via the bloodstream. This method was found to be somewhat ineffective, as sufficient concentrations of the drug in and around the tumour were difficult to achieve without raising the toxicity to an intolerable level, due to the drug's low water solubility. A solution to this problem was later developed in the form of Cremophore EL, which was a suspension of the drug in a thick gel designed to be injected directly into the tumour. This method gave results that were only slightly better because the gel, although concentrating the drug in the desired area, was too thick to allow easy diffusion of the drug, thus not allowing the bulk to come into direct contact with the tumour cells and produce the desired effect. The frequent dosing that was required to maintain sufficient concentration again caused nonspecific toxicity, now in the vicinity of the tumour. The nanoparticle method is simply the next step in the process of finding an effective way of administering Paclitaxel, which aside from these problems has a wide range of effective anti-cancer activity.
In their work researchers (Sahoo et al., 2004 ) took a similar approach to administering the drug preparation, in that they also injected the nanoparticle preparation into the tumour. This was done partly to minimise the uptake of the spheres by macrophages and partly to improve the comparison of the effectiveness of this new treatment with Cremophor EL. The results indicated the survival rates of the mice treated with the Cremophor EL suspension were much lower than those treated with conjugated nanoparticles, although about the same as those treated with unconjugated nanoparticles. This shows that even unconjugated nanoparticles are as effective as Crempophor EL, while those that are also conjugated for targeting produce much better success rates. Furthermore, tumour growth, which was also monitored, was actually reversed with the use of conjugated nanoparticles at 24 mg/kg for the period of observation (Sahoo et al., 2004) .
One of the main conclusions to be drawn from these results is that conjugation of nanospheres (spherical nanoparticles) with targeting moieties greatly increases the effectiveness of a treatment. Any further research should be directed primarily in this area. Experience has shown that as we become progressively more skilled at identifying and modelling proteins, we also become better able to create artificial recognition molecules to effectively target these proteins, as mentioned in the preventive treatment section. Thus, further research will likely yield tumour-specific recognition ligands, which will allow us to tailor treatments to specific kinds of cancer. Perhaps in the not so distant future, we may be able to draw some blood from the patient, determine patient-specific/tumour-specific proteins, and send the data away to a lab. A few days later, a drug will be prepared that is highly effective against that specific type of cancer, embedded in nanoparticles, which are conjugated to artificial ligands ready to target the exact proteins that are specific to that patient.
• A second potential treatment involves absorption of light by gold nanoparticles (Pitsillides et al., 2003) . The method involves gold-coated nanoparticles conjugated to recognition ligands. Gold nanoparticles are frequently used in electron microscopy due to their high electron density. They also have distinct absorption peaks in between ~500-600 nm wavelength electromagnetic radiation (Link and El-Sayed, 1999 ) for different nanoparticle sizes as shown in Figure 8 . The underlying principle is that these particles readily absorb laser radiation and convert it to heat. To achieve the desired results, one may use commercially available gold nanoparticles and conjugate them to certain recognition molecules engineered to target CD8+ lymphocyte cells.
CD8, a cell surface protein, was used to distinguish cells among the general population of lymphocytes under study (Pitsillides et al., 2003) . Iron-oxide doped latex microspheres were also used in a concurrent study. To distinguish between CD8+ and regular lymphocytes under a fluorescence microscope, a fluorescent dye (R-phycoerythrin) conjugated to anti-CD8 IgG antibodies was used. Each type of sphere was conjugated to recognise the CD8+ protein imbedded within the cell membranes. The cells under study were first labelled with a general fluorescent dye that was non-cell-specific. This fluorescent dye was allowed to penetrate into the cytoplasm. The cells were then conjugated to both kinds of particles and the population labelled with latex microspheres was analysed by a fluorescence microscope. The effectiveness of the gold nanosphere method was gauged by analysing uptake of propidium iodide (C 27 H 34 N 4 I 2 , CAS: 25535-16-4) and subsequently measuring FITC fluorescence. The experiment consisted of two stages. During the first stage, the cells were briefly irradiated with a 532 nm or 565 nm laser. The duration of the pulses for the nanoparticle run was kept under 10 ns. For the microparticle run, the duration was kept under 1 µs. A microsphere run was carried out in order to allow observation under a light microscope as well as to compare its effectiveness to the nanosphere run. During the microscale experiment, the frame-grabber was used to record an image of the field approximately 100 ns after irradiation. The observations showed an interesting phenomenon known as cavitation due to phase transition. Cavitation is caused by the rapid temperature increase, which causes the water in the immediate vicinity of the particle to vapourise and to form a bubble as the vapour pressure overcomes the surface tension of the liquid. As the bubble grows in volume, it cannot sustain itself and collapses inward. The impact can be so violent that for smaller particles, it can cause fragmentation. Particle fragments have been observed which support this phenomena (Pitsillides et al., 2003) . This phenomena is believed to be the mechanism of cell destruction and responsible for the subsequently observed cell death. Cell death was confirmed by the leaking out of the fluorescent dye due to lacerated cell membranes.
Theoretical calculations of the temperature distribution in and around the spheres were carried out using the Goldenberg and Tranter heat transfer model (Goldenberg and Tranter, 1952) assuming uniformly heated homogeneous spheres embedded in an infinite homogeneous medium. When appropriate numerical values for radiation rate, radius and conductivities are inserted in the model the researchers found that irradiation of the spheres caused a rapid increase in temperature of the order of thousands of degrees Kelvin which is the reason for sudden formation of bubble and its rapid growth.
The conclusions to be drawn from this study are that light-responsive nanoparticles are potent tools for nanosurgery and cancer treatment. They are highly effective cell-destruction agents that can be targeted quite effectively at specific cell types by the use of the appropriate recognition molecules. As one of the leading applications of nanoparticles, this technique deserved extra attention from prospective researchers. In fact, some current investigations (Loo et al., 2001; Hirsch et al., 2003) have successfully applied this technology to biological systems in vivo.
A study done on mice has recently shown to be just as effective in leading to complete remission and elimination of malignant tumours, and is scheduled to enter clinical trials in humans in the near future (Farokhzad et al., 2001 ).
• Finally, the third nanoparticle method for direct cell destruction to be discussed is the magnetic nanoparticle hyperthermia method (Jordan et al., 1999) . It is hypothesised that the relatively old concept of hyperthermia can be combined with methods in nanotechnology to achieve previously unequalled positive results. Hyperthermia is a biological term used to describe the phenomenon that occurs when living cells or tissues are heated to temperatures slightly above the highest that can occur naturally. In humans, the hyperthermic temperature range falls between 41ºC and 46ºC.
When human cells are briefly brought into this temperature range, almost irreversible cell damage can result. An added effect of these changes is the lowered resistance of cells to radiation damage. Magnetic fluid hyperthermia is a method for cancer treatment that has been around for nearly 50 years. It involves using small magnetic particles that respond to an externally applied magnetic field by heating up.
This study was done in vivo with murine mammary carcinoma cells transplanted in the hind leg of mice. The mice were treated for 30 minutes at a steady intratumoural temperature of 47ºC. The study was the first to use nanosised particles to achieve hyperthermic conditions and has managed to prove the method to be quite effective.
In the study, nanoparticles were used to coat the tumour cells, which were then subjected to magnetic fields from 50 kHz to 100 kHz using a prototype AC magnetic field applicator. One benefit of using this method is that it can be applied internally, thus opening up the prospect of treating types of cancer that involve deep-seated tissues and organs. An added benefit is that cells that have picked up some of the particles cannot get rid of them, and thus, every daughter cell will have one half of the amount of particles present on the mother cell. If the initial concentration of the particles is sufficiently high, there is a possibility of re-treatments. The particles, which consist of aminosilan shell magnetite with a core diameter of about 10 nm, are strongly adhesive to human colon adenocarcinoma cells. However, this effect is either far decreased or not observed at all with other kinds of cells, making prospective conjugation to recognition ligands a necessity. When this study was done, conjugation nanotechnology (Santra and Tan, 2001) was not yet readily available. However, with all of the recent advances in the production of artificial antibodies and other recognition ligands, this method could be greatly improved by targeting the particles to specific types of cells (Johannsen et al., 2001 ). Source: Link and El-Sayed (1999) Aside from destroying cells directly, we can take a more elegant approach to tumour elimination. Mass and energy balance are well understood and are widely used in all types of science and engineering. Furthermore, these concepts are quite general, and can be applied to other fields as well, such as medicine. The general principles of mass balance, energy conservation and entropy production are applicable to bio systems as well as industrial processes. Thus, we can define the malignant tumour as our bio system and proceed to investigate the mass, energy and entropy inputs, outputs and accumulations.
Since our ultimate goal is to destroy the tumour, we realise that this can be achieved by limiting or eliminating the inputs of the needed nutrients and the useful energy that are vital to its growth and survival. Likewise, we can limit the outputs, which are necessary for the tumour cells to get rid of toxic waste products that are left over from the multitude of biochemical reactions continuously taking place. Furthermore, basic anatomy and biology tell us that cells within the human body get a vast majority of their nutrients and energy from the bloodstream, and likewise use the bloodstream to eliminate the toxins. Cells that are cut off from circulation quickly undergo necrosis and are effectively eliminated. Therefore, our goal is to separate the tumour from the circulation in order to kill it.
Numerous studies have explored the possibility of isolating cancer tumours from the bloodstream. One that is exemplary will be discussed here (Reynolds et al., 2003) . The underlying principle of the study is that the cells within the growing tumour produce and send out basic Fibroblast Growth Factor (bFGF) accompanied by Vascular Endothelial Growth Factor (VEGF), the combination of which stimulates the development of new capillaries that grow into the tumour (Figure 9 ). The study used nanoparticles specifically designed to target cells that make up these freshly created capillaries by delivering to them ATPm-RAF, or pre-synthesised RNA (ribonucleic acid) strands responsible for inducing apoptosis. The nanoparticles consisted of a core of phospholipids, with the hydrophobic tails directed inward, which gave the outer surface of the particle a net negative charge. The charge allowed for facilitated conjugation of any desired DNA or RNA sequence to the particle's surface. Also imbedded in the core were integrin-antagonist lipids, whose tails were identical to the phospholipids tails, and whose heads served as the targeting moieties for the epithelial cells. As a result of intravenous treatment with these nanoparticles in live mice, the newly formed capillaries were destroyed; cutting off the tumour from circulation and preventing further growth. The tumour cells underwent necrosis and were eliminated shortly thereafter.
Nanoparticle science and technology
Clearly, the most current disease-time nanotechnology-based treatment methods involve the use of some type of nanoparticle. Therefore, a brief description of bio-medical nanoparticles is in order. A general nanoparticle consists of a core that can have a constitution ranging from very simple to highly complex, depending on the intended application. The core can contain one or several payload drugs, as well as permeation and visibility enhancers. The surface may be bare or conjugated to targeting ligands, like antibody (Figure 10) (Singer, 1959) or polyethylene glycol ligands (Figure 11 ) (Tabata et al., 1997; Mehvar, 2000) to prevent macrophage uptake of the nanoparticle.
In addition to nanoparticles made of gold, iron oxide, titanium oxide, and zinc oxide other nanostructures, as discussed below, hold promise for novel nanotechnology-based cancer treatments. An antibody (also called an immunoglobulin) is a protein that is manufactured by lymphocytes (a type of white blood cell) to neutralise an antigen or foreign protein (Mansoori, 2005; Galfre and Milstein, 1981; Evan et al., 1985) . Monoclonal antibodies, a special type of antibody designed in the laboratory, which can guide nanoparticle medications directly to the cancer cell Figure 11 Polyethylene glycol (PEG) as ligand. With chemical formula (-CH 2 CH 2 O-) n , (MW ≤ 10 kD) PEG is very attractive as nanoparticle, drug or protein carrier (Mehvar, 2000) . For coupling proteins to PEG, usually monomethoxy PEG [CH 3 (-O-CH 2 -CH 2 ) n -OH] is first activated by means of an activating agent (linker) before the addition of the particle Source: Delgado et al. (1992) 
Fullerenes
Fullerenes are quite stable molecules and their stability makes them good candidates for safely delivering highly toxic substances to tumours (Moghimi et al., 2001) . Fullerenes are large carbon-cage molecules. By far the most common one is C 60 , also called a 'buckyball', but some other relatively common ones are C 70 , C 76 , and C 84 . The subscripts, of course, refer to the number of carbon atoms that can be found in the structure. Fullerene cages are about 0.7-1.5 nm in diameter. Fullerenes are small compared to many organic molecules such as proteins. Chemically, they are quite stable; breaking the balls requires temperatures of over 1000°C. At much lower temperatures (a few 100°C), fullerenes will 'sublime', which means vapour will form directly from the solid. Fullerene as a nanoparticle has found various applications in cancer treatment (Moghimi et al., 2001; Andrievsky and Burenin, 2001; Tabata et al., 1997) . As an example the preventive and medicinal action of Hydrated Fullerene (HyFn) as shown in Figure 12 has been investigated (Andrievsky and Burenin, 2001) . In another study (Tabata et al., 1997 ) the photodynamic effect of PEG-modified fullerene on tumours was studied. 
Carbon nanotubes
Different kinds of carbon nanotubes (CNTs) have different properties. Multi-walled carbon nanotubes (MWNTs) can bind with proteins, as various experimental techniques have revealed that covalent bonds formed between polymer radicals and acid-treated carbon nanotubes (Chen et al., 2001) . To achieve the attachment of nanotubes to proteins, two issues must be considered. The first is the state of dispersion of the CNT in the solution and the second is the interfacial adhesion between the CNT and the protein.
In Figure 13 schematics of a functionalised single-walled carbon nanotube with Cyanine Dye #3 Labelled DNA (Cy3-DNA) as reported by Kam et al. (2001) . Carbon nanotubes (Chen et al., 2001; Teker et al., 2001; Kam et al., 2001 ) possess interesting property of adsorbing materials on their surface and heating up upon absorbing near-infrared light wave. In one study (Kam et al., 2001) it is shown that cancer cells tend to be coated with folate receptors, whereas normal cells are not. This is how carbon nanotubes target to cancer cells. When exposed to near-infrared light, carbon nanotubes quickly release excess energy as heat (~70°C), which can kill cancer cells. Kam et al. (2001) 
Quantum dots
A quantum dot is a semiconductor nanocrystal with a diameter of a few nanometers ( Figure 14) . Because of its small size it behaves like a potential well that confines electrons in three dimensions to a region on the order of the electrons' de Broglie wavelength in size.
Figure 14
Semiconductor nanosise crystalline quantum dots possess quantised energy levels with unique optical and electronic properties. They confine electrons in three dimensions to a region, on the order of the electrons' de Broglie wavelength with varied sizes and shapes, which can be precisely controlled, containing anything from a single electron to a set of hundreds or even thousands of electrons. Modification in their size and structure exhibit many colours in the entire ultraviolet-visible spectrum (Figure 15) Quantum dots are photoluminescent with a wide absorption spectrum and a narrow emission peak (Figure 15 ). Quantum dots photoluminescence is used in bio-imaging, biological labelling and diagnostics (Murray et al., 1993; Gao et al., 2001 Gao et al., , 2004 . Their immense photo-stability aids in the ability to track cell processes for extended periods of time and to give more insight on intermolecular relationships. Size-tunable light emission, improved signal brightness, resistance against photobleaching and simultaneous excitation of multiple fluorescence colours are some of the unique optical and electronic properties of quantum dots. Bioconjugated quantum dots have produced new possibilities for multiplexed and ultrasensitive imaging of biomolecular targets in animal cells.
Figure 15
A Typical UV-visible absorption and emission spectra for quantum dots. The first excitation peak is at the 1550 nm wavelength and the emission peak is at 1630 nm. This data is for PbSe QD nanocrystals of ~5.5 nm size manufactured by Evident Technologies: www.evidenttech.com
The semiconductor material used in quantum dots is potentially toxic to the cells and humans. Polymer-encapsulated quantum dots are nontoxic for in vivo use. However, their long-term in vivo toxicity and degradation need further study. Much more research still needs to be done to achieve reproducible and robust surface functionalisation and to develop flexible bioconjugation techniques for the use of quantum dots (Medintz et al., 2001; Bakalova et al., 2004) .
Magnetic nanoparticles
The magnetic effect of magnetic nanoparticles is due to superparamagnetic iron oxides (SPIO) core(s), typically Fe 2 O 3 and Fe 3 O 4 , which do not retain magnetism when removed from a magnetic field (Moffat et al., 2001; Tartaj et al., 2003) . The iron oxide core(s) surrounded by a silicon coat or a layer of polymer such as dextran or polyacrylamide. (Figure 16 ). Nanoscale magnetic particles with a variety of compositions, sizes and stabilisers have been prepared in the past four decades. Several applications for these materials exist, as ferrofluids (Raj et al., 1995) in the solid state, primarily in the biomedical and magnetic recording industries. Magnetic nanoparticles were first discovered in a biological organism (chitons) in 1962 (Lowenstam, 1962) . Numerous current and potential commercial biomedical applications exist for systems comprised of magnetic nanoparticles. Current applications are focused on in vitro applications such as:
• cell and cell organelle detection and separation
• immobilisation, isolation and determination of biologically active compounds. nanoparticle (Moffat et al., 2001) . Their paramagnetic characteristics have made them good candidates for in vivo cancer cell destruction through hyperthermia. Their polymer coating prevents their cytotoxicity and allows them to move freely in the organism without adhesion or reaction Magnetic nanoparticles are also noteworthy for in vivo diagnostic purposes. Magnetic nanoparticles can be used to target drug delivery, as hyperthermia agents to destroy cancer cells and have potential to move the particles to specific sites in an organism, and hold them until treatment is finished. Their sizes are in the range of 50-300 nm. They have applications in magnetic immunoassay and also as Magnetic Resonance Imaging (MRI) contrasts. Magnetic nanoparticles are sensitive to magnetic fields and electromagnetic radiation. This property induces hyperthermia for cancer treatment (Jordan et al., 1999) .
Liposomes
Liposomes consist of synthetic microscopic fat globules of lipids (Figure 17 ), which are incredibly biodegradable. They are nanoscale closed vesicles consisting of a single lipid bilayer. They are manufactured to enclose medications for drug delivery like chemotherapy (Basu and Basu, 2002) . The fatty layer on liposome confines and protects the enclosed drug until the liposome is delivered and adheres to the outer membrane of target cancer cells. By this process drug toxicity to healthy cells is decreased and its efficacy may be increased. Liposome therapy is a well-developed technology for delivery of chemotherapy drugs (Silva et al., 2001; Torchilin and Weissig, 2003; Duncan et al., 2005) .
Figure 17
Cross section of a liposome: a synthetic lipid bilayer vesicle that fuses with the outer cell membrane and is used to transport small molecules (drug, etc.) to tissues and into cells
Source: Mansoori (2005) 
Dendrimers
Dendrimers are unique macromolecules that have applications in developing strategies for nano-scale globular shapes with small cores. Dendrimers (Figure 18 ), generally possess multiple branches which can be used to carry a variety of agents fulfilling various functions at once. Dendronised polymers are cylindrical macromolecules that are composed of a linear polymeric backbone and dendritic side chains (Figure 18 ). The thickness of the polymers is in the range of several nanometers. These nano objects have gained interest because of their cylindrical structure, which provides new unique properties that could be applied within the emerging field of nanotechnology (Zhang et al., 2003) . For example, DNA/PAMAM (Polyamidoamine) dendrimer complex is used for DNA delivery to cell nucleus due to its high transfection efficiency and very low toxicity. Poly-amidoamine (PAMAM) dendrimers are favourite candidates for use as the backbone of multitasking therapeutics because of their well-defined surface functionality, good water solubility, low polydispersity and their lack of immunogenicity (Choi et al., 2001) . For example, the controlled surface modification followed by conjugation of folate and fluorescein moieties on the surface of a dendrimer is shown to yield molecules capable of targeting to tumour cells through folate receptors (Quintana et al., 2001 ). There are many ongoing research activities (Fréchet and Tomalia, 2002) in the design of new dendrimers with preferred molecular functionalities.
Diamondoids
Diamondoids are cage hydrocarbons with little adverse health risks, good therapeutic effects and many useful derivatives (Figure 19 ) (Mansoori, 2005; Ramezani and Mansoori, 2006) . Extensive amount of investigations have been performed related to synthesis of new diamondoid derivatives with better therapeutic actions and less adverse effects.
Figure 19 Low molecular weight diamondoids
Source: Mansoori (2005) and Ramezani and Mansoori (2006) The smallest diamondoid molecule is named adamantine. Adamantane derivatives are readily synthesised (Orzeszko et al., 2000) and have found many medicinal applications including for cancer treatment. For example, it has been proven that adamantylamino-pyrimidines and -pyridines are strong stimulants of tumour necrosis factor-(TNF-) (Kazimierczuk et al., 2001) . TNF is referred to a substance that can improve the body's natural response to cancer by killing the cancer cells. Another example is 1,6 -diaminodiamantane (Malik et al., 1991) which possesses an antitumour and antibacterial activity. Attaching some short peptidic sequences to adamantane makes it possible to design novel antagonists. The bradykinin antagonist, which is used as an anti-cancer agent, is an example (Reissmann et al., 2000) . Also dimethyladamantylmaleimide has been effective for growth inhibition of human colon cancer .
A wise course of action would be to direct our collective research and development efforts into improving and expanding nanoparticle science. Nanoparticles already have a multitude of applications and will likely have many more in the near future. Any discoveries that are made in this area will surely benefit fields other than medicine and cancer research, and should therefore be designated as an interdisciplinary goal.
Detection and diagnosis through nanotechnology
Another important issue to be addressed is cancer diagnosis through nanotechnology. In order to provide early and thus more effective cancer treatment, early detection of the disease is crucial. Two approaches to cancer detection may be envisioned and they include
• in vitro (laboratory-based) diagnostics
• in vivo diagnostics.
Although in vivo detection is still a challenge, in vitro detection studies have recently produced some impressive breakthroughs (Jain, 2005) .
In vitro (laboratory-based) diagnostics
Laboratory-based (in vitro) nanotechnology methods are based on the concept of computer chips. For example, with the use of some recent discoveries in nanoarrays, we can now detect multiple biomolecular markers at very low concentrations in various biological fluids. There are currently two equally effective nanoarray methods.
The first method involves nanowires (Figure 20) connected to a high-sensitivity electronic ammeter. Each nanowire is designed to be a good binding site for a specific biomolecule. The biofluid under study is passed through a channel where it is allowed to come into direct contact with the wire array. The conductance of the wires changes as the molecules bind, and detection is made possible by measuring the conductance in real time (Zheng et al., 2005) .
The second method involves a nanoarray of Atomic Force Microscope (AFM) cantilevers which are equipped with antibodies specific to selected molecules. The array is submerged in a biofluid where the molecules that are present are allowed to bind to the antibodies. As they bind, they cause the levers to deflect, and the deflection is measured by a combination of a highly focused laser beam and sensitive photodetectors, with a technique similar to that used in AFM. Both methods can yield data that are highly accurate, even with concentrations in the range of parts per million.
In vivo diagnostics
Some promising in vivo techniques are currently under development. One method is to use nanoarrays similar to those described above. However, due to conditions that are much more adverse in a living patient, significantly higher concentrations of the desired molecules are necessary for accurate detection. Another method is to implant biosensors directly into the patient and to have them relay gathered information to an external data collector. The major problem with these methods that still remains unresolved is biofouling, or the nonspecific adoption of serum proteins to the sensors. Since serum proteins are present in healthy as well as malignant environments, the accuracy of the measurements can be greatly impaired. This problem has been in the way of effective in vivo detection for quite some time. Ferrari (2005) suggests more novel measuring methods must be developed that are dependent on other physical properties, and from which the biofouling signal can be decoupled using appropriate mathematical algorithms. A solution containing telomerase is delivered to the device array, and telomerase binds in a concentration-dependent process. (Bottom) Subsequent addition of dNTPs leads to telomerase-catalysed primer extension/elongation which can be detected (Zheng et al., 2005) . The abbreviation 'dNTPs' stands for Deoxynucleotide-triphosphates, the units from which DNA molecules are constructed, each carrying a single nitrogenous base. They include adenine, guanine, cytosine or thymine
Conclusion
Prevention, diagnosis and treatment of cancer have always been a formidable medical challenge. In fact, cancer has long been considered an incurable disease and it is grouped with Hepatitis C and AIDS. Throughout the bulk of human history, cancer tended to be fatal in those who were unfortunate to develop it. Cancer will continue to be a big problem since it is a disease related mostly to age. As our population average age increases due to medical advances cancer will be a major disease of the aging. Over the past 150 years, many innovative and groundbreaking techniques have been developed in order to treat cancer (Diamandopoulus, 1996) . These techniques range from brute surgical removal to X-ray irradiation to system wide flooding with anticancer agents. However, each of these approaches has its own series of undesirable side effects that are both dangerous and damaging to the overall health of the patient. On the contrary, very recent breakthroughs in nanotechnology have managed to change all that. Now at last there is hope for a cure that is effective and can be made it safe.
Although there is still plenty of work to be done, some very promising new nanotechnology treatment methods are in the works. Nanotechnology treatments can be used in both the preemptive and in the disease-time approaches to dealing with cancer. As we become better able to engineer more sophisticated nanodevices and to equip them with effective targeting techniques for biomolecules, we will gain the ability to treat various kinds of cancer more and more effectively.
An important aspect of cancer treatment is its early detection. There have been significant improvements largely due to breakthroughs, both, in the bottom-up and in the top-down nanotechnology. Developments in such areas as in nanoarrays, nanosensors, liposomes, monoclonal antibodies, improved nanoparticles (dendrimers, diamondoids, gold-based nanoparticles, magnetic nanoparticles, and quantum dots) and nanoelectronics are making early detection, prevention and treatment with a high degree of accuracy and ease possible. Also other recent discoveries and inventions in nanotechnology are suggesting that a safe and effective cure for cancer is just around the corner.
The goal of the US National Cancer Institute is to eliminate the suffering and death from cancer by the year 2015. Achievement of this goal in the battle against cancer seems to be mostly due to the potential successes of dealing with cancer through nanotechnology, sufficient research funds and a determination to succeed. Of course the hope is to turn cancer into a manageable ailment that we can treat and we can live with.
Glossary

AFM.
A tip-based pizo-scanning instrument able to image surfaces to molecular accuracy by mechanically probing their surface contours. It can be used for analysing the material surface all the way down to the atoms and molecules level. A combination of mechanical and electronic probe is used in AFM to magnify surfaces up to 100,000,000 times to produce 3-D images of them Antagonist effect. Effect of a drug that neutralises or counteracts the effects of another drug Antibody. A special protein produced by the cells of the immune system of humans and higher animals in response to the presence of a specific antigen. It recognises and helps fight infectious agents and other foreign substances (antigens) that invade the body by binding to them , where h is the Planck, k B is the Boltzmann constant, m is the particle's rest mass, and T is the absolute temperature. Λ is the mean quantum mechanical wavelength of the molecules at temperature T. In other words, it expresses the momentum term in terms of thermal energy DNA = Deoxyribonucleic Acid. The carrier of genetic information, which passes from generation to generation. Every cell in the body, except red blood cells, contains a copy of the DNA Endothelial cell. A thin, flattened cell that lines the interior surface of blood vessels Immunogenicity. The ability of a substance (i.e., antigen; vaccine) to stimulate an immune response Integrin-antagonist lipid. Peptide that inhibits tumour growth, induces apoptosis, prevents cell-cell adhesion and found on white blood cell and platelet surface Intermolecular relationships. Forces and potentials due to attraction and repulsion between molecules Ligand. A radical, an ion, a molecule, or a molecular group that binds to another chemical entity to form a larger complex Macrophage. A type of white blood cell that surrounds and kills microorganisms, removes dead cells due to apoptosis, and stimulates the action of other immune system cells Melanoma. A form of skin cancer that arises in melanocytes, the cells that produce the skin pigment. It is induced by exposure to significant sun exposure or high levels of UV radiation Metabolite. In genetics it refers to the organic substances resulting from enzymatic reactions 
